Last reviewed · How we verify
NCT05716958
Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT
trial testing Digital Breast Tomosynthesis in Breast Cancer in 262 participants. Completed in 28 February 2023.
28 February 2023
Quick facts
| Lead sponsor | Lunit Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 262 |
| Start date | 22 March 2022 |
| Primary completion | 28 February 2023 |
| Estimated completion | 28 February 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Digital Breast Tomosynthesis
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Lunit Inc.
Who can join
22 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate Effectiveness of Lunit INSIGHT DBT in the assistance of detection and diagnosis of breast cancer during 3D mammography interpretation
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05716958
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Digital Breast Tomosynthesis
Trials testing the same drug.
- NCT07140965 — The Impact of Surgeon-Interpreted Intraoperative Margin Assessment During Breast Conserving Surgery on Postoperative Tre · suspended
- NCT06059300 — Digital Breast Tomosynthesis for the Dutch National Breast Cancer Screening Program · NA · active not recruiting
- NCT03417024 — Automated Breast Ultrasound Case Collection Registry · terminated
- NCT02698202 — Screening for Breast Cancer With Digital Breast Tomosynthesis · NA · completed
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Lunit Inc. trials
Trials by the same sponsor.
- NCT05619029 — Study to Evaluate the Effectiveness of the Device in Detection of Abnormal Findings on X-ray · completed
- NCT05615298 — Study to Evaluate Effectiveness of Investigational Device in the Assistance of Detection and Diagnosis of Breast Cancer · completed
- NCT05614232 — Study to Evaluate the Effectiveness of the Device in Detection of Abnormal Findings on Chest X-ray · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05716958 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lunit Inc.
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05716958.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing